Next-Generation Therapeutics for Infectious Diseases Conquer the Global Spotlight, Finds Frost & Sullivan

Next-Generation Therapeutics forNext-Generation Therapeutics for Infectious Diseases Conquer the Global Spotlight, Finds Frost & Sullivan PR Newswire LONDON, March 25, 2014 - Resistance to current drugs spurs treatment innovation in influenza, respiratory syncytial virus, chlamydia and gonorrhoea The available antivirals for commonly occurring infections such as respiratory syncytial virus (RSV) and influenza are characterised by variable response, poor tolerability and suboptimal dosing regimens, limiting their regular use and efficacy. Likewise, the development of resistance to almost every recommended antibiotic for bacterial infections like chlamydia and gonorrhoea makes treatment complicated. Successful commercialisation of next-generation therapeutics and the imminent arrival of novel innovative vaccine technologies are expected to address these issues and generate strong growth in the infectious diseases therapeutics market. New analysis from Frost & Sullivan's Global Infectious Diseases Therapeutics Market—Influenza, RSV, Chlamydia, and Gonorrhoea finds the influenza vaccine industry is witnessing a shift from conventional egg-based vaccines, which use live attenuated and inactivated viruses, to novel DNA-based, recombinant, sub-unit, and even microbial vector-based approaches. These technologies are becoming popular for their cost benefits and potential for mass production in the event of a pandemic.